Survivorship Data in Prostate Cancer: Where Are We and Where Do We Need To Be?

Autor: Beth Russell, Katharina Beyer, Ailbhe Lawlor, Monique J. Roobol, Lionne D.F. Venderbos, Sebastiaan Remmers, Erik Briers, Sara J. MacLennan, Steven MacLennan, Muhammad Imran Omar, Mieke Van Hemelrijck, Emma Smith, James N'Dow, Karin Plass, Maria Ribal, Nicolas Mottet, Robert Shepherd, Tom Abbott, Ken Mastris, Lisa Moris, Michael Lardas, Thomas Van den Broeck, Peter-Paul Willemse, Nicola Fossati, Karl Pang, Riccardo Campi, Isabella Greco, Mauro Gacci, Sergio Serni, Anders Bjartell, Ragnar Lonnerbro, Alberto Briganti, Daniele Crosti, Roberto Garzonio, Giorgio Gandaglia, Martina Faticoni, Grant office, Chris Bangma, Maria Jongerden, Derya Tilki, Anssi Auvinen, Teemu Murtola, Tapio Visakorpi, Kirsi Talala, Teuvo Tammela, Aino Siltari, Stephane Lejeune, Laurence Colette, Simona Caputova, Delielena Poli, Sophie Byrne, Luz Fialho, Ashley Rowland, Neo Tapela, Nicola Di Flora, Kathi Apostolidis, Valerie Lemair, Bertrand De Meulder, Charles Auffray, Nesrine Taibi, Ayman Hijazy, Albert Saporta, Kai Sun, Shaun Power, Nazanin Zounemat Kermani, Kees van Bochove, Azadeh Tafreshiha, Chiara Bernini, Denis Horgan, Louise Fullwood, Marc Holtorf, Doron Lancet, Gabi Bernstein, Sheela Tripathee, Manfred Wirth, Michael Froehner, Beate Brenner, Angelika Borkowetz, Christian Thomas, Friedemann Horn, Kristin Reiche, Markus Kreuz, Andreas Josefsson, Delila Gasi Tandefelt, Jonas Hugosson, Jack Schalken, Henkjan Huisman, Thomas Hofmarcher, Peter Lindgren, Emelie Andersson, Adam Fridhammar, Monica Tames Grijalva, Susan Evans-Axelsson, Frank Verholen, Jihong Zong, John-Edward Butler-Ransohoff, Todd Williamson, Reg Waldeck, Amanda Bruno, Ekaterina Nevedomskaya, Samuel Fatoba, Niculae Constantinovici, Carl Steinbeisser, Monika Maass, Patrizia Torremante, Emmanuelle Dochy, Federica Pisa, Marc Dietrich Voss, Kishore Papineni, Jing Wang-silvanto, Robert Snijder, Xuewei Wang, Mark Lambrecht, Russ Wolfinger, Sherinne Eid, Soundarya Palanisamy, Samiul Haque, Laurent Antoni, Angela Servan, Katie Pascoe, Paul Robinson, Joana Lencart, Bertrand Jaton, Heidi Turunen, Olavi Kilkku, Pasi Pohjanjousi, Olli Voima, Liina Nevalaita, Keijo Punakivi, Sarah Seager, Shilpa Ratwani, Katarzyna Grzeslak, James Brash, Elaine Longden-Chapman, Danny Burke, Muriel Licour, Sarah Payne, Alan Yong, Flavia Lujan, Sophia Le Mare, Jan Hendrich, Michael Bussmann, Juckeland, Kotik, Christian Reich

Publikováno v: European Urology Open Science, Vol 59, Iss , Pp 27-29 (2024)

Cancer survivorship was recently identified as a prostate cancer (PCa) research priority by PIONEER, a European network of excellence for big data in PCa. Despite being a research priority, cancer survivorship lacks a clear and agreed definition, and

Externí odkaz: https://doaj.org/article/0e8513a8ae754937a693cd11a79baf4a

Real-world effectiveness, long-term safety and treatment pathway integration of radium-223 therapy in patients with metastatic castration-resistant prostate cancer

Autor: Joe M. O’Sullivan, Rana R. McKay, Kambiz Rahbar, Karim Fizazi, Daniel J. George, Bertrand Tombal, Anja Schmall, Per Sandström, Frank Verholen, Neal Shore

Publikováno v: Frontiers in Medicine, Vol 9 (2022)

Radium-223 dichloride (223Ra) is an α-emitter approved for the treatment of metastatic castration-resistant prostate cancer (mCRPC) with bone metastases, but without visceral involvement. Despite being a life-prolonging therapy (LPT), 223Ra remains

Externí odkaz: https://doaj.org/article/58b28ce9627446ce89d0ec6430b4a8bb

Safety and Survival Outcomes of177Lu-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer with Prior223Ra treatment: The RALU Study

Autor: Kambiz Rahbar, Markus Essler, Kim M. Pabst, Matthias Eiber, Christian la Fougère, Vikas Prasad, Philipp Rassek, Ergela Hasa, Helmut Dittmann, Ralph A. Bundschuh, Wolfgang P. Fendler, Milena Kurtinecz, Anja Schmall, Frank Verholen, Oliver Sartor

Publikováno v: Journal of Nuclear Medicine. 64:574-578

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5c84b508399c995894786db43e7e4e8f
https://doi.org/10.2967/jnumed.122.264456

Real-world patient characteristics associated with survival of 2 years or more after radium-223 treatment for metastatic castration-resistant prostate cancer (EPIX study)

Autor: Daniel J. George, Neeraj Agarwal, Oliver Sartor, Cora N. Sternberg, Bertrand Tombal, Fred Saad, Kurt Miller, Niculae Constantinovici, Helen Guo, John Reeves, XiaoLong Jiao, Per Sandström, Frank Verholen, Celestia S. Higano, Neal Shore

Publikováno v: Prostate Cancer and Prostatic Diseases, Vol. 25, no. 2, p. 306-313 (2022)

Background The real-world EPIX study was conducted to gather information about the characteristics of patients with metastatic castration-resistant prostate cancer (mCRPC) who survived ≥2 years after treatment with the alpha-emitter radium-223. Met

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fcad1ba113b1677261c32e5dff7372df
https://doi.org/10.1038/s41391-021-00488-0

Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS Trial

Autor: Maha Hussain, Bertrand Tombal, Fred Saad, Karim Fizazi, Cora N. Sternberg, E. David Crawford, Neal Shore, Evgeny Kopyltsov, Arash Rezazadeh Kalebasty, Martin Bögemann, Dingwei Ye, Felipe Cruz, Hiroyoshi Suzuki, Shivani Kapur, Shankar Srinivasan, Frank Verholen, Iris Kuss, Heikki Joensuu, Matthew R. Smith

Publikováno v: Journal of Clinical Oncology.

PURPOSE For patients with metastatic hormone-sensitive prostate cancer, metastatic burden affects outcome. We examined efficacy and safety from the ARASENS trial for subgroups by disease volume and risk. METHODS Patients with metastatic hormone-sensi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::8e7ab5dc25bb4d6d809eb98520b76a3f
https://doi.org/10.1200/jco.23.00041